

[CLAIMS]

1. Use of an anti-T cell antigen-binding molecule in the manufacture of a pharmaceutical composition for use in combination therapy comprising an anti-T cell antigen-binding molecule, wherein the pharmaceutical composition is to be administered in combination for use in its combination therapy with a cytokine inhibitor, wherein the cytokine inhibitor is to be administered before administration of the pharmaceutical composition.
2. The use of claim 1, wherein the cytokine inhibitor is to be administered 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day before the administration of the pharmaceutical composition, or on the same day as but before said administration.
3. The pharmaceutical composition use of claim 1 or 2, wherein the cytokine inhibitor is to be further administered before, simultaneously with, or after administration of the pharmaceutical composition.
4. The pharmaceutical composition use of claim 1 or 2, wherein the cytokine inhibitor is to be further administered before or simultaneously with the administration of the pharmaceutical composition.
5. The pharmaceutical composition of any one of claims 1 to 3, wherein the cytokine inhibitor is administered 6 days, 5 days, 4 days, 3 days, 2 days, or 1 day before the administration of the pharmaceutical composition, or on the same day as but before said administration.
6. The pharmaceutical composition of any one of claims 1 to 4, wherein the cytokine inhibitor is to be further administered after the administration of the pharmaceutical composition.
7. The pharmaceutical composition use of any one of claims 1 to 4, wherein the cytokine inhibitor is to be further administered on the same day as, or 1 day, 2 days, 3 days, 4 days, 5 days, or 6 days after the administration of the pharmaceutical composition.
8. The pharmaceutical composition use of any one of claims 1 to 5, wherein the cytokine inhibitor is to be further administered when CRS or signs of CRS develop after the administration of the pharmaceutical composition.
9. The pharmaceutical composition use of claim 6, wherein the CRS is CRS in Grade 2 or higher or Grade 3 or higher.
10. The pharmaceutical composition of any one of claims 1 to 7, wherein the cytokine inhibitor is administered after the administration of the pharmaceutical composition.
11. The pharmaceutical composition of claim 1 or 8, wherein the cytokine inhibitor is administered when CRS or signs of CRS develop after the administration of the pharmaceutical composition.
12. The pharmaceutical composition of claim 8 or 9, wherein the CRS is CRS in Grade 2 or higher or Grade 3 or higher.

~~11.9.~~ The ~~pharmaceutical composition~~use of any one of claims 1 to ~~108~~, wherein the cytokine inhibitor is an inhibitor of one or more cytokines selected from IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, IL-1Ra, IL-2R, IFN- α , IFN- γ , MIP-1 α , MIP-1 β , MCP-1, TNF α , GM-CSF, G-CSF, CXCL9, CXCL10, CXCR factor, VEGF, RANTES, eotaxin, EGF, HGF, FGF- β , CD30, CD30L, CD40, CD40L, ferritin, and RAGE.

~~12.10.~~ The ~~pharmaceutical composition~~use of any one of claims 1 to ~~119~~, wherein the cytokine inhibitor is an anti-IL6R antibody.

~~13.11.~~ The ~~pharmaceutical composition~~use of any one of claims 1 to ~~1210~~, wherein the cytokine inhibitor is Tocilizumab, and wherein Tocilizumab is to be administered at 8 mg/kg or less per dose for a patient weighing 30 kg or more and at 12 mg/kg or less per dose for a patient weighing less than 30 kg.

~~14.12.~~ The ~~pharmaceutical composition~~use of any one of claims 1 to ~~1311~~, wherein a corticosteroid is not to be administered before or simultaneously with the administration of the pharmaceutical composition.

~~15.13.~~ The ~~pharmaceutical composition~~use of any one of claims 1 to ~~1412~~, wherein a corticosteroid is to be further administered before, simultaneously with, or after the administration of the pharmaceutical composition.